Alanosine
(Redirected from SDX-102)
Jump to navigation
Jump to search
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C3H7N3O4 |
Molar mass | 149.106 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Alanosine (also called SDX-102)[1] is a substance that has been studied for the treatment of pancreatic cancer.[2] It is an antimetabolite. It is used as one of a few experimental treatments for patients with deadly pancreatic cancer when the main chemotherapeutic treatment regimen of gemcitabine is no longer useful.[needs update]
References
- ^ PubChem. "Alanosine". pubchem.ncbi.nlm.nih.gov. Retrieved 2021-04-08.
- ^ Yu J (November 2001). "Alanosine (UCSD)". Current Opinion in Investigational Drugs. 2 (11): 1623–30. PMID 11763167.
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs with no legal status
- Drugboxes which contain changes to watched fields
- Wikipedia articles in need of updating from May 2021
- All Wikipedia articles in need of updating
- Antimetabolites
- Amino acid derivatives
- 2,3-Diaminopropionic acids
- Nitrosamines
- Experimental cancer drugs
- Toxic amino acids
- All stub articles
- Antiinfective agent stubs